Eton Pharmaceutcials Inc (ETON) Stock Price, Quote & News

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyros...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 847 787 7361

Website: www.etonpharma.com

Address:

21925 W. Field Parkway, Suite 235, Deer Park, United States

Dbarnyard May. 13 at 2:22 AM

$HROW Some people made fun of me when I suggested that the stock price of $ETON would overtake HROW. Perhaps the market caps will cross soon as well. Then those people can apologize to me 😄

0 · Reply

bryantboy99 May. 12 at 2:28 PM

$ETON never thought that $HROW would be the same price.

0 · Reply

Tadeo17 May. 7 at 3:59 PM

$ETON dajeeeeee!!!!!

0 · Reply

CharlieeMungerTWITS May. 5 at 4:55 PM

$ETON wowza

0 · Reply

bryantboy99 May. 5 at 2:27 PM

$ETON she's gonna catch $HROW before much longer

0 · Reply

bryantboy99 May. 5 at 9:27 AM

$ETON something to look forward to next week. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-report-first-quarter-2026-financial-results

0 · Reply

Dbarnyard May. 4 at 6:06 PM

$HROW Wow, had HROW held on to its shares of $ETON, what would that stake be worth today? $100M? $125M? Crazy...

2 · Reply

CharlieeMungerTWITS May. 4 at 2:56 PM

$ETON beats mode

0 · Reply

VeltrixCapitalOfficial May. 4 at 2:55 PM

$2.30 on $ETON here. 🥷 30% GAIN. ☢️☢️☢️

0 · Reply

Blockwave1 May. 4 at 2:55 PM

$2.30 on $ETON here. 🥷 30% GAIN. ☢️☢️☢️ TURN ON POST NOTIFICATIONS 🔔

0 · Reply

Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

May 4, 2026, 4:30 PM EDT - 8 days ago

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

2026-05-01T11:06:48.000Z - 12 days ago

Eton Pharmaceuticals announces relaunch of Hemangeol

May 1, 2026, 6:50 AM EDT - 12 days ago

Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

2026-04-27T11:01:30.000Z - 16 days ago

Eton Pharmaceuticals says first patient dosed in study of ET-700

Apr 27, 2026, 6:50 AM EDT - 16 days ago

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

2026-04-16T11:31:33.000Z - 27 days ago

Eton Pharmaceuticals appoints Judith Matthews as CFO

Apr 16, 2026, 6:50 AM EDT - 27 days ago

Eton Pharmaceuticals Announces CFO Succession Plan

2026-03-20T16:35:59.000Z - 7 weeks ago

Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright

2026-03-20T12:56:32.000Z - 7 weeks ago

Eton Pharmaceuticals price target raised to $35 from $30 at Craig-Hallum

2026-03-20T12:27:07.000Z - 7 weeks ago

Eton Pharmaceuticals price target raised to $31 from $26 at B. Riley

Mar 19, 2026, 4:30 PM EDT - 7 weeks ago

Eton Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-19T20:17:23.000Z - 7 weeks ago

Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year

2026-03-19T20:16:43.000Z - 7 weeks ago

Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M

Mar 19, 2026, 4:05 PM EDT - 7 weeks ago

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-12T15:56:30.000Z - 2 months ago

Eton Pharmaceuticals participates in a conference call with Craig-Hallum

Mar 3, 2026, 4:30 PM EST - 2 months ago

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

2026-03-03T14:22:27.000Z - 2 months ago

Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum

2026-03-02T12:42:44.000Z - 2 months ago

Eton in-licenses U.S. commercialization rights to HEMANGEOL from Pierre Fabre

Mar 2, 2026, 7:27 AM EST - 2 months ago

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

2026-03-02T11:17:08.000Z - 2 months ago

Eton Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright

2026-02-25T19:15:17.000Z - 2 months ago

Eton Pharmaceuticals trading resumes

2026-02-25T18:56:15.000Z - 2 months ago

Eton Pharmaceuticals announces FDA approval for Desmoda Oral Solution

Feb 25, 2026, 1:51 PM EST - 2 months ago

US FDA approves Eton Pharma's hormonal disorder drug

Feb 25, 2026, 1:47 PM EST - 2 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

2026-02-25T17:35:36.000Z - 2 months ago

Eton Pharmaceuticals trading halted, news pending

Feb 20, 2026, 6:50 AM EST - 2 months ago

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

2026-02-02T11:55:37.000Z - 3 months ago

Eton licenses U.S. marketing rights to ultra-rare disease product candidate

Feb 2, 2026, 6:50 AM EST - 3 months ago

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

2025-12-01T14:45:10.000Z - 5 months ago

Eton Pharmaceuticals management to meet with B. Riley

Nov 24, 2025, 4:30 PM EST - 6 months ago

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

Nov 12, 2025, 4:30 PM EST - 6 months ago

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Nov 6, 2025, 4:30 PM EST - 6 months ago

Eton Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:30 PM EDT - 7 months ago

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

2025-09-17T18:05:17.000Z - 8 months ago

Eton Pharmaceuticals management to meet virtually with Craig-Hallum

Aug 20, 2025, 6:50 AM EDT - 9 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

2025-08-07T20:42:01.000Z - 9 months ago

Eton Pharmaceuticals reports Q2 non-GAAP EPS 3c, consensus 2c

2025-08-07T20:41:47.000Z - 9 months ago

Eton Pharmaceuticals sees reaching annual revenue run rate of $80M in Q3

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Eton Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 7:00 AM EDT - 10 months ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 8, 2025, 6:50 AM EDT - 11 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Jun 27, 2025, 6:50 AM EDT - 11 months ago

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

May 28, 2025, 5:28 PM EDT - 1 year ago

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

May 14, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

May 13, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

May 1, 2025, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 28, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Mar 25, 2025, 2:30 AM EDT - 1 year ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Mar 18, 2025, 10:00 AM EDT - 1 year ago

Eton Pharmaceuticals Transcript: Investor Day 2025

Mar 18, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Mar 14, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Mar 4, 2025, 10:00 AM EST - 1 year ago

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Mar 4, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Mar 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Feb 7, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Feb 6, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Jan 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Dec 20, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Dec 3, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Nov 25, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Nov 12, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 3, 2024, 6:30 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 5:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

May 13, 2024, 9:30 AM EDT - 2 years ago

Eton Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 2 years ago

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 2 years ago

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Apr 29, 2024, 4:30 PM EDT - 2 years ago

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Dbarnyard May. 13 at 2:22 AM

$HROW Some people made fun of me when I suggested that the stock price of $ETON would overtake HROW. Perhaps the market caps will cross soon as well. Then those people can apologize to me 😄

0 · Reply

bryantboy99 May. 12 at 2:28 PM

$ETON never thought that $HROW would be the same price.

0 · Reply

Tadeo17 May. 7 at 3:59 PM

$ETON dajeeeeee!!!!!

0 · Reply

CharlieeMungerTWITS May. 5 at 4:55 PM

$ETON wowza

0 · Reply

bryantboy99 May. 5 at 2:27 PM

$ETON she's gonna catch $HROW before much longer

0 · Reply

bryantboy99 May. 5 at 9:27 AM

$ETON something to look forward to next week. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-report-first-quarter-2026-financial-results

0 · Reply

Dbarnyard May. 4 at 6:06 PM

$HROW Wow, had HROW held on to its shares of $ETON, what would that stake be worth today? $100M? $125M? Crazy...

2 · Reply

CharlieeMungerTWITS May. 4 at 2:56 PM

$ETON beats mode

0 · Reply

VeltrixCapitalOfficial May. 4 at 2:55 PM

$2.30 on $ETON here. 🥷 30% GAIN. ☢️☢️☢️

0 · Reply

Blockwave1 May. 4 at 2:55 PM

$2.30 on $ETON here. 🥷 30% GAIN. ☢️☢️☢️ TURN ON POST NOTIFICATIONS 🔔

0 · Reply

ApexEquityVault May. 4 at 2:53 PM

$2.30 on $ETON here. 🥷 30% GAIN. ☢️☢️☢️ TURN ON POST NOTIFICATIONS 🔔

0 · Reply

anderam May. 4 at 2:37 PM

$ETON I have avg $3.58.

3 · Reply

Doozio May. 4 at 2:30 PM

$XBI $AXSM BODI. That wen da huckleberries get $ETON n $DRUG z get $LGND ary ONTO 🐒🍌🧠⏰♾️

1 · Reply

TechridyStocks May. 2 at 5:42 PM

$ETON

0 · Reply

topstockalerts May. 2 at 12:21 AM

$ETON steady push… nothing crazy but very clean

0 · Reply

STACKD0E May. 1 at 11:48 PM

$ETON 🙃✨️

0 · Reply

Manwiththeplan May. 1 at 5:00 PM

$ETON wow, i was here @ 3$. Sold my whole big bag @ $ 6-10 . I was happy with the profit. Look were it is now. Great work. Biotech can be beautiful!

0 · Reply

momoinvestor May. 1 at 4:50 PM

$ETON Sean is a beast... the guy simply executes and delivers... much respect for him and his history !

0 · Reply

BesTrades1 May. 1 at 4:23 PM

$ETON $25 by end of the day

3 · Reply

BesTrades1 May. 1 at 4:19 PM

$ETON good short

0 · Reply

Olivia_Strickland May. 1 at 4:13 PM

$ETON +19.9% to 28.91 on the HEMANGEOL relaunch with the specialty pharmacy distribution setup, that's a real revenue lever for a $789M cap not just a press release pop. +89.6% in 3 months and 1.6x avg vol means the rare disease pipeline Source: https://tapeboard.com/chart/ETON

0 · Reply

Market Cap	816.42M
Revenue (ttm)	79.95M
Net Income (ttm)	-4.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	35.94
Profit Margin	-5.75%
Debt to Equity Ratio	1.17

Volume	246,700
Avg Vol	410,450
Day's Range	N/A - N/A
Shares Out	27.36M
Stochastic %K	71%
Beta	0.82
Analysts	Strong Sell
Price Target	$39.88